Medications like Semaglutide (the active ingredient in Ozempic and Wegovy) and Tirzepatide (in Mounjaro and Zepbound) have completely changed the landscape
Novo Nordisks once-daily oral Wegovy (25 mg semaglutide) is now approved for adults with obesity, or overweight patients with at least one weight-related condition, marking the first pill-based GLP-1 option indicated for both weight loss and cardiovascular risk reduction
Signs Its Time to Schedule an Evaluation You may want to see a dermatologist if you notice: Shedding that continues beyond 2 to 3 months without slowing down Visible thinning, such as a widening part or reduced volume More hair than usual coming out during brushing or washing Hair that feels noticeably finer or less dense over time These changes can indicate that your hair cycle has been significantly disrupted or that additional factors are contributing
Diagnostics (Basel, Switzerland) 15 , 580 (2025)
Overall, GLP-1 agonists are safe with the most common side effects of nausea, vomiting, diarrhoea and constipation being only mild to moderate in severity in most people
Body Composition Changes During Weight Reduction With Tirzepatide in the SURMOUNT-1 Study of Adults With Obesity or Overweight
